에 대한 최신 뉴스 Arbutus Biopharma (NASDAQ:ABUS) 주식

Arbutus Biopharma

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Future Pandemics

Health Care

Legal

ABUS

MRNA

수요일 4월 3일, Arbutus Biopharma(NASDAQ:ABUS)의 주식은 회사가 법정에서 Moderna Inc(NASDAQ:MRNA)에 대한 소송을 제기할 권한을 부여받은 후 20% 이상 급등했다.



What Happened: Arbutus는 첫 소송에서 Moderna에 대해 클레임을 제기하는데 성공했는 데, 이 소송의 내용은 Moderna가 개발한 코로나 백신의 기반이 된

아르부투스 주식, 모더나와의 코로나 백신 특허 쟁송을 앞두고 급등

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

HSBC analyst Erwan Rambourg upgrades Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) from Hold to Buy and raises the price target from $80 to $99.

News

Upgrades

Price Target

Analyst Ratings

HSBC Upgrades Estee Lauder Cos to Buy, Raises Price Target to $99

Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#NYSE">CHRO</a>), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Reverse Stock Split is intended to increase the market price per share of the Company's Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the "NYSE American") in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and into LNHC, Inc. and the related approximately $50 million in capital to be raised from a group of strategic investors led by Murchinson (together, the "Proposed Transactions").

Stock Split

CHRO

Channel Therapeutics Announces 10-For-1 Reverse Split Ahead Of LNHC Merger, $50M Investment Led By Murchinson

Platinum prices have surged to their highest levels since 2014, driven by tightening supply, speculative investor flows, and a wave of buyers turning to the metal as a cheaper alternative to gold.
The <a target="_blank" href="https://www.benzinga.com/topic/platinum" rel="noreferrer noopener">precious metal</a> climbed as high as $1,435 per ounce in the Asian trading session on Friday before taking a breather in the rally that gained over 50% from the April lows.
A key catalyst behind the rally is a deepening supply deficit. The World Platinum Investment Council (WPIC) recently noted that the platinum market is expected to record a deficit of 966 koz this year, followed by 992 koz and 896 koz in 2024 and 2023, respectively.
Also Read: <a href="https://www.benzinga.com//node/45858594">Platinum Rallies To 4-Year High: Is $1,200 Just The Start?</a>
"On the supply side, mine production remains at multi-year lows, while recycling has failed to rebound to pre-pandemic levels, " Edward Sterck, WPIC's Director of Research, <a target="_blank" href="https://platinuminvestment.com/about/60-seconds-in-platinum/2025/06/18" rel="noreferrer noopener">said </a>in the report published on June 18.
Sterck noted that demand, while down 4% year-on-year due to lower industrial glass demand, remains resilient. "Jewelry and investment demand are outperforming expectations, with bar and coin sales in China in particular showing strong momentum," he added.
Much of the current demand boom is being driven by jewelry and technological applications. In China, gold jewelry sales plummeted 32% in the first quarter, while platinum jewelry fabrication <a target="_blank" href="https://platinuminvestment.com/files/873451/WPIC_Platinum_Quarterly_Q1_2025.pdf" rel="noreferrer noopener">rose by 26%</a> as consumers sought a more affordable alternative. Retailers responded by boosting their platinum inventories.
Technology-driven demand is also a factor, as platinum (traditionally a component of catalyst converter metals for internal combustion engines) plays a crucial role in hydrogen energy systems, particularly in proton exchange membrane electrolyzers.
Another factor driving platinum's momentum is its growing role as a "gold alternative." With gold trading at historic highs above $3,000 an ounce and institutions like Goldman Sachs seeing a further <a target="_blank" href="https://www.goldmansachs.com/insights/articles/why-gold-prices-are-forecast-to-rise-to-new-record-highs" rel="noreferrer noopener">rise to $3,700</a> by the end of 2025, platinum remains notably undervalued in comparison.
This widening price gap between the two metals has made platinum an increasingly attractive option for investors seeking exposure to precious metals without paying gold's premium.
"Gold has almost doubled in two years," Nicky Shiels of MKS Pamp said according <a target="_blank" href="https://www.ft.com/content/69d15526-97d2-476a-9699-e341f26118f2" rel="noreferrer noopener">to</a> the Financial Times, "and this is the next iteration of that trade—investors are asking ‘what's next?' and platinum is answering that call."
Looking ahead, analysts expect the bullish trend in platinum to persist. WPIC forecasts continued deficits through 2029, citing structural weaknesses in supply and growing industrial and investment demand. With visible above-ground stocks declining and no significant recovery in mine production anticipated soon, the fundamentals suggest further price upside.
Price Watch: Valterra Platinum (OTCPK: AGPPF) closed at $45.41. The stock is up nearly 45% year-to-date.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/46006672" target="_blank" rel="noreferrer noopener">Options Corner: Safe-Haven Demand Could Spark A Golden Payout For This Royal Gold Call Spread</a></li>
</ul>
Photo by yMediaStock via Shutterstock

Large Cap

Commodities

Markets

Trading Ideas

AGPPF

PALL

PGMFF

First Trust ISE Global Platinum Index Fund

PLTM

PPLT

Investors Seek Gold Alternative - Platinum Hits $1,400 As Supply Deficit Deepens

A man who retired at 49 with a steady $4,000 monthly pension and a paid-off home now finds himself drowning in $85,000 in personal loans plus another $5,000 in credit card debt. At 65, he's asking his sons for $1,000 a month to help stay afloat.
The problem? His kids are in their prime working years and have their own financial responsibilities, including plans to fund graduate school.
During a <a href="https://www.youtube.com/watch?v=JVkQdBtsuoc">recent episode</a> of "The Ramsey Show," co-hosts Jade Warshaw and John Delony didn't sugarcoat their advice: helping your parents is admirable — but not when it puts your own future at risk.
Don't Miss:
<ul class="wp-block-list">
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
<h2 class="wp-block-heading">A Tough Ask From Dad</h2>
The caller said his father, mostly healthy after a recent minor heart attack, has been out of the workforce for over 15 years. His pension provides about $48,000 annually, and he typically gets an extra $7,000 to $12,000 in end-of-year bonuses.
Still, his loan payments total around $2,500 each month, leaving him short. To close the gap, he's asking his sons to front him $1,000 a month now, with a promise to pay them back when the bonus comes through.
But Ramsey personalities <a href="https://www.benzinga.com/personal-finance/management/25/06/46017023/this-dave-ramsey-caller-is-spending-half-his-78000-income-on-legal-fees-for-custody-battles-with-two-women-he-got-pregnant-in-college">Warshaw</a> and Delony said this isn't just a financial dilemma — it's an emotional one.
"He's put you and your brother in an incredibly awkward position," Delony said. "On behalf of dads everywhere, I'm sorry he did that to you. ‘Cause dads aren't supposed to do that to their boys."
Trending: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
<h2 class="wp-block-heading">Retired Too Early — And With Too Much Debt</h2>
Retiring at 49 is uncommon — and risky without serious <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/01/42805298/with-the-new-generation-beta-come-new-financial-planning-challenges-and-opportunities">financial planning</a>. The caller explained his dad spends his time on a small hobby farm, which might bring in $7,000 to $10,000 if sold, but isn't enough to offset the mounting debt.
Warshaw questioned the decision to walk away from the workforce so early, especially with loans still on the table. "He for sure has six good working years in him," she said, adding that he could bring in an extra $1,000 per month without putting pressure on his children.
<h2 class="wp-block-heading">The Money's Already Spoken For</h2>
The caller said he technically has the funds to help, but they're set aside for his wife's graduate school. Warshaw was quick to push back: "It's earmarked for something else, so that means you don't have it."
Using earmarked money, especially for long-term goals like education, can sabotage a couple's <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/06/46024255/7-silent-wealth-drains-that-are-sabotaging-your-future">financial future</a> and strain the marriage in the process.
<h2 class="wp-block-heading">Time for a Wake-Up Call</h2>
Delony emphasized the need for an honest conversation between father and sons. "You&#8217;re broke, man," he said, describing what the son needs to tell his father directly.
That conversation should include hard questions: Is Dad willing to return to work? Sell assets? Downsize? Or is he simply looking for an easier way out — one that comes at his children's expense?
See Also: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
According to Delony, it's not about being ungrateful or harsh — it's about setting boundaries and making responsible choices. He said it would be different if the caller's father didn't have food or shelter, but "this isn't that."
<h2 class="wp-block-heading">Love, Support — And Limits</h2>
Warshaw and Delony both stressed that while supporting aging parents is an honorable thing to do, it shouldn't come at the cost of your own stability.
"He put a wedge in y&#8217;all&#8217;s father-son relationship by saying, ‘Hey, I know your wife&#8217;s in school. I know y&#8217;all are thinking about having a family. I know y&#8217;all are thinking these things. I don&#8217;t care," Delony said. "Don&#8217;t further that wedge by creating a business transaction between the two of you."
At the end of the day, love doesn't always mean saying yes. In this case, as Ramsey's team made clear, saying no may be the most loving — and responsible — choice of all.
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>

Personal Finance

He Retired At 49 With A $4K Monthly Pension, But His $85K Debt Has Him Asking His Kids For Help – 'Ramsey Show' Hosts Weigh

Wells Fargo analyst Sam Reid maintains Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) with a Overweight and raises the price target from $125 to $130.

Wells Fargo Maintains Overweight on Toll Brothers, Raises Price Target to $130

Stephens &amp; Co. analyst Trey Grooms downgrades GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) from Overweight to Equal-Weight and maintains the price target from $95 to $95.

Downgrades

Stephens & Co. Downgrades GMS to Equal-Weight, Maintains Price Target to $95

Wells Fargo analyst Sam Reid maintains KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) with a Underweight and lowers the price target from $52 to $50.

Wells Fargo Maintains Underweight on KB Home, Lowers Price Target to $50

Wells Fargo analyst Joseph O'Dea maintains Acuity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) with a Equal-Weight and raises the price target from $285 to $320.

Wells Fargo Maintains Equal-Weight on Acuity, Raises Price Target to $320

Google Labs, Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google&#8217;s home for AI experiments, <a href="https://blog.google/technology/google-labs/doppl/" target="_blank" rel="noreferrer noopener">introduced</a> a new fashion-centric AI app aimed at style enthusiasts and digital creatives.
The experimental tool, called Doppl, leverages advanced artificial intelligence to help users explore and visualize how different outfits might appear on animated avatars of themselves.
Doppl expands on Google&#8217;s previous virtual try-on feature by introducing new experimental elements.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/46134725/google-cloud-hires-former-oracle-cfo-as-ai-race-heats-up" rel="noreferrer noopener">Google Cloud Hires Former Oracle CFO As AI Race Heats Up</a>
Users can upload images, whether personal snapshots or screenshots from the web, and see how those outfits might look on themselves using a lifelike digital model.
This includes both still previews and animated renderings that simulate motion and fabric flow.
The app allows users to store their favorite looks, share them across social platforms, and refine their personal style based on inspiration drawn from real-life encounters or online discovery.
Whether the outfit is seen on a friend or in a store window, Doppl turns a single image into a personalized fashion experience.
Developed under the umbrella of Google Labs, Doppl remains in an early testing phase.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, GOOG stock has lost over 6% in the past year. Investors can gain exposure to the stock via&nbsp;ETF Opportunities Trust T-Rex 2X Long Alphabet Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/GOOX#BATS">GOOX</a>).
Price Action: GOOG shares are trading higher by 0.37% to $175.08&nbsp;at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46132953/fake-news-former-engineer-joining-meta-refutes-sam-altmans-100m-golden-pass-accusation-to-poach-openai-talent" target="_blank" rel="noreferrer noopener">&#8216;Fake News:&#8217; Former Engineer Joining Meta Refutes Sam Altman&#8217;s $100M Golden Pass Accusation To Poach OpenAI Talent</a></li>
</ul>
Image via Shutterstock

Equities

Tech

General

GOOG

GOOGL

ETF Opportunities Trust T-Rex 2X Long Alphabet Daily Target ETF

GOOX

Try Any Outfit At Home Before Buying - Google Drops New AI App

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and will expire five years after the date of issuance, and the Series E short-term warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and will expire 18 months after the date of issuance. The closing of the offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions.
Total gross proceeds to the Company from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be $5.0 million. The potential additional gross proceeds to the Company from the warrants, if fully-exercised on a cash basis, will be $10.0 million. No assurance can be given that any of such warrants will be exercised. The Company intends to use the net proceeds from this offering to fund clinical trials, maintain and extend its patent portfolio, and for working capital and other general corporate purposes. &nbsp;

Offerings

BBLG

BBLGW

Bone Biologics Prices $5M Public Offering At $4.00/Shr With Series D And E Warrants

<h2 class="wp-block-heading">New On The Block</h2>
Bahama Breeze may soon be <a href="https://www.benzinga.com/general/restaurants">gone with the wind</a>. 
Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) is considering selling the Caribbean-inspired chain or repurposing all its locations.
The decision comes after Darden closed 15 Bahama Breeze restaurants in May, leaving just 28. Guru Focus <a href="https://www.gurufocus.com/news/2938406/darden-to-explore-strategic-alternatives-for-bahama-breeze-chain?r=caf6fe0e0db70d936033da5461e60141">reported</a> that CEO Rick Cardenas told analysts that future investments in the brand are off the table.
Initially launched in the 1990s, Bahama Breeze served up tropical vibes with dining options like coconut shrimp and empanadas. However, after a strategic review, Darden decided it was time to focus on other properties, such as the never-ending-pasta-bowl innovator Olive Garden.
<h2 class="wp-block-heading">Updates From The Block</h2>
Businessman Mark Walter has agreed to acquire a majority stake in the NBA's Los Angeles Lakers from the Buss Family Trust. Jeanie Buss will continue to oversee team operations. Walter, already a minority owner, also leads TWG Global, which holds stakes in several sports properties.
The Buss family has owned the Lakers since 1979, overseeing 11 NBA championships and shaping one of the most recognized franchises in global sports. The team has featured iconic players such as Magic Johnson, Kareem Abdul-Jabbar, Kobe Bryant, Shaquille O'Neal and LeBron James.
The deal is expected to close in late 2025, pending NBA approval and other standard conditions.
Guggenheim Securities is advising Walter, with legal support from Davis Polk &amp; Wardwell LLP. ArentFox Schiff LLP represents the Lakers and the Buss Family Trust.
More Updates:
<ul class="wp-block-list">
<li>Recall in 2021 how Best Buy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) acquired remote care management platform Current Health. It&#8217;s now selling it <a href="https://www.linkedin.com/feed/update/urn:li:activity:7343300338491305984/">back</a> to co-founder Christopher McGhee for $400 million.</li>
<li>Maserati isn&#8217;t for sale. That&#8217;s according to Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>), the owner, which <a href="https://www.reuters.com/business/autos-transportation/jeep-maker-stellantis-weighs-sale-among-options-maserati-sources-say-2025-06-20/?utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=newsletter_axioscloser&amp;stream=top">responded</a> to a Reuters report.</li>
<li>U.S. antitrust regulators approved Mars&#8216; proposed $35.9 billion purchase of snackmaker Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>). In Europe, however, antitrust <a href="https://www.benzinga.com/m-a/25/06/46113916/mars-just-got-the-green-light-for-its-36b-deal-but-europe-might-blow-it-up">regulators are investigating the deal</a>.</li>
<li>New Zealand-based accounting software firm Xero will acquire U.S. bill-pay platform Melio for an initial $2.5 billion, according <a href="https://www.wsj.com/business/deals/xero-to-buy-melio-for-initial-2-5-billion-in-u-s-growth-play-eb0d46af?mod=deals_news_article_pos2">to</a> the Wall Street Journal. Melio shareholders, including Accel and Thrive Capital, will receive $360 million in Xero shares. Xero, which reported approximately $1.26 billion in revenue for its last fiscal year, stated that revenue could double over the next three years, excluding anticipated synergies. Melio CEO Matan Bar will lead Xero's U.S. business post-acquisition.</li>
<li>Bank of New York Mellon placed an offer for Chicago-based Northern Trust, which has a market value of more than $21 billion. The Trump administration has <a href="https://www.reuters.com/markets/deals/big-bank-deals-stalled-by-trump-volatility-even-officials-signal-deregulation-2025-03-14/">signaled</a> a greater willingness to approve large banking deals, but few have been completed.</li>
<li>Woody Johnson is the latest rich American to buy a different football club. The billionaire agreed to pay just $215 million for a &#8220;significant&#8221; stake in Premier League club Crystal Palace, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-06-23/ny-jets-owner-woody-johnson-agrees-deal-for-crystal-palace-stake?sref=TBDibEcD">reports</a>. On the sell side is John Textor. Let&#8217;s hope Crystal Palace has better luck than the New York Jets, which has been under the miserable ownership of Johnson since January 2000.</li>
<li>Unilever signed an agreement to acquire personal care brand Dr. Squatch from growth equity firm Summit Partners. The price tag was not disclosed, but Women&#8217;s Wear Daily <a href="https://wwd.com/beauty-industry-news/skin-care/unilever-personal-care-acquisition-dr-squatch-1237941602/">reported</a> that the company&#8217;s sales exceeded $400 million.</li>
</ul>
<h2 class="wp-block-heading">Off The Block</h2>
<ul class="wp-block-list">
<li>The NBA&#8217;s board of governors approved the $1.5 billion sale of the Minnesota Timberwolves and WNBA's Minnesota Lynx from longtime owner Glen Taylor to an investment group led by entrepreneur Marc Lore and former MLB star Alex Rodriguez. The unanimous vote concludes a four-year back-and-forth process that included arbitration after Taylor attempted to cancel the deal earlier this year. Taylor, who bought the Timberwolves in 1994 to prevent a relocation to New Orleans, leaves after 31 years with the team. Lore and Rodriguez pledged to keep the teams in Minnesota.</li>
</ul>
<ul class="wp-block-list">
<li>Parkland (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PKI#TSX">PKI</a>), a Canadian fuel distributor, confirmed that shareholders voted in favor of a $9.1 billion takeover by Sunoco (YSE: SUN). The deal will form America&#8217;s largest independent fuel distributor.</li>
</ul>
<h2 class="wp-block-heading">Bankruptcy Block</h2>
<ul class="wp-block-list">
<li>You can still place bids on assets owned by Monster and CareerBuilder. The two online job search websites, which merged last year, <a href="https://www.wsj.com/articles/careerbuilder-monster-to-sell-businesses-in-bankruptcy-9daa38dd">filed</a> for Chapter 11 bankruptcy. So far, JobGet is looking to buy at least one asset. Canada-based Valsoft Corporation and Canadian media firm Valnet are keen on acquiring others, including Military.com, which Monster bought in 2004 for $39.5 million. Tough competition is to blame for the restructuring, says CEO Jeff Furman, citing Indeed, LinkedIn, and Glassdoor. Private equity firm Apollo Global Management holds a minority stake in the company.</li>
</ul>
<a href="https://www.benzinga.com/m-a/25/06/46038749/deal-dispatch-boston-red-sox-owner-sets-sights-on-la-liga-club-at-home-files-for-bankruptcy">For last week&#8217;s edition of Deal Dispatch, click here</a>. 
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46125266/thank-you-elon-musks-longtime-aide-reportedly-fired-days-after-public-praise">&#8216;Thank You, Elon:&#8217; Musk&#8217;s Longtime Aide Reportedly Fired Days After Public Praise</a></li>
</ul>
Image: Edited by Benzinga using Shutterstock

Asset Sales

Sports

STLA

TSX:PKI

Deal Dispatch: Darden Cools On Bahama Breeze, NBA M&A Heats Up

Wells Fargo analyst Finian O'Shea maintains Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) with a Overweight and raises the price target from $21 to $22.

ARCC

Wells Fargo Maintains Overweight on Ares Capital, Raises Price Target to $22

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.27</td>
<td align="right">0.30</td>
<td align="right">0.73</td>
<td>1.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.37</td>
<td align="right">1.36</td>
<td align="right">0.63</td>
<td>4.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">106.96</td>
<td align="right">0.53</td>
<td align="right">0.49</td>
<td>105</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">146.00</td>
<td align="right">0.66</td>
<td align="right">0.45</td>
<td>673</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.45</td>
<td align="right">0.28</td>
<td align="right">0.34</td>
<td>3.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">86.03</td>
<td align="right">0.28</td>
<td align="right">0.32</td>
<td>35.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">251.60</td>
<td align="right">0.53</td>
<td align="right">0.21</td>
<td>14.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">87.96</td>
<td align="right">0.18</td>
<td align="right">0.20</td>
<td>880</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">134.47</td>
<td align="right">0.25</td>
<td align="right">0.18</td>
<td>3.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.85</td>
<td align="right">0.06</td>
<td align="right">0.11</td>
<td>292.6K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.15</td>
<td align="right">-0.02</td>
<td align="right">-0.03</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 27, 2025

U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Friday.
Shares of Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) fell sharply in today's pre-market trading after the company posted mixed <a href="https://www.benzinga.com/quote/CNXC/earnings">second-quarter results</a>.
Concentrix reported quarterly earnings of $2.70 per share, which missed the analyst consensus estimate of $2.75. Quarterly revenue came in at $2.42 billion, which beat the Street estimate of $2.38 billion
Concentrix shares dipped 8% to $50.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) declined 14.2% to $12.83 in pre-market trading after the company announced an $85 million public offering.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) fell 14.2% to $3.14 in pre-market trading after surging more than 32% on Thursday.</li>
<li>AdaptHealth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) fell 8.6% to $8.61 in pre-market trading after gaining around 5% on Thursday.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) declined 8.4% to $11.65 in pre-market trading.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) fell 5.1% to $22.60 in pre-market trading.</li>
<li>OMS Energy Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMSE#NASDAQ">OMSE</a>) fell 4.6% to $6.80 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46115042/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-june">Top 2 Tech And Telecom Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutetrstock

AHCO

CNXC

CRMD

CRML

OMSE

USAR

Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session

RBC Capital analyst Drew McReynolds reiterates Corus Entertainment (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CJR#TSX">CJR</a>) with a Sector Perform and maintains C$0.2 price target.

Reiteration

TSX:CJR

TSX:CJR/B

RBC Capital Reiterates Sector Perform on Corus Entertainment, Maintains C$0.2 Price Target

Select Medical Corporation today announced it signed a membership interest purchase agreement with Ballad Health to jointly operate Select Specialty Hospital – Tri-Cities, a critical illness recovery hospital in Kingsport, Tenn. The facility, licensed as long-term acute care, will be a hospital-in-hospital located in Ballad Health's Indian Path Community Hospital.&nbsp;
Select Medical will serve as the majority owner and managing partner of the 46-bed joint venture hospital with Ballad Health. The hospital, which is currently owned and operated by Select Medical, will relocate from Ballad Health's Bristol Regional Medical Center to Indian Path Community Hospital following regulatory approval.

Select Medical Signs Membership Interest Purchase Agreement With Ballad Health To Jointly Operate Select Specialty Hospital – Tri-Cities

RSLS

ReShape Lifesciences Regains Nasdaq Compliance Under Minimum Stockholders Equity Requirement

On June 25, 2025, Ralliant Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RALW#NYSE">RALW</a>), a spin-off of Fortive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTVW#NYSE">FTVW</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) <a href="https://gsbresearch.com/product/spinoff-analysis-fortive-and-ralliant-begin-when-issued-trading/">commenced when-issued trading</a> on the NYSE. 
Earlier on September 4, 2024, FTV announced plans to separate its Precision Technologies business into a separate publicly listed company, Ralliant Corp, via a tax-free spin-off transaction. The parent will retain the Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) business segments, boasting a portfolio with 50% recurring revenue. We see the spin-off as a move to streamline operations and accelerate business growth, thereby unlocking value for shareholders. The spin-off will allow Fortive to focus on high-growth, high-margin businesses in software and connected devices. The Precision Technologies business is more capital-intensive and has stable but slower growth than the parent. The separation will allow Ralliant to allocate capital and resources more efficiently towards its needs, such as R&amp;D for advanced instrumentation or acquisitions within its niche.
The record date for the distribution of Ralliant shares was June 16, 2025. Each FTV shareholder will receive 1 share of Ralliant for every 3 shares of FTV held as of the record date. The regular-way trading will begin on June 30, 2025. Ralliant will trade under the ticker ‘RAL' and Fortive (ex Ralliant) will continue to trade under the ticker ‘FTV'. The spin-off of Ralliant will be effective on June 28. The transaction is intended to qualify as tax-free to Fortive shareholders.
Following the completion, Olumide Soroye, the current leader of Fortive's intelligent operations division, will assume the position of CEO. Meanwhile, Tami Newcombe, the current overseer of the Precision Technologies and Advanced Health-Care units, will take charge of Ralliant Corp.
As part of the transaction, FTV (ex RAL) will receive $1.15 billion in dividend from Ralliant Corp. RAL will assume debt to pay the cash dividend to FTV and commence its journey as a standalone company with a leverage of 1.9x.
INVESTMENT HIGHLIGHTS
Fortive (ex Ralliant)
Post the separation, Fortive will comprise the portfolio brands such as Accruent, Fluke, Gordian, Censis, Provation, currently operating under Fortive's two business segments – Intelligent Operating Solutions (iOS) and Advanced Healthcare Solutions (AHS). The two business segments generate nearly 50% recurring revenue and have demonstrated lower volatility across cycles.
FTV (ex Ralliant) will be $4 billion in revenues, with 65% adjusted gross margins and 29% adjusted EBITDA margins. The business generated about $1 billion in free cash flow over the last twelve months with an adjusted net income to FCF conversion of more than 100%. Over the last five years, it has delivered 4% core revenue CAGR.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="906" height="117" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8.png" alt="" class="wp-image-14985" style="width:850px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8.png 906w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8-300x39.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8-768x99.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></figure>
Intelligent Operating Solutions (IOS). IOS is Fortive's largest segment, accounting for nearly 70% of the revenue post spin-off. It houses flagship brands such as Fluke (electrical and industrial test tools), Industrial Scientific (gas detection and worker safety), Accruent and Gordian (enterprise asset management), and ServiceChannel (facility maintenance SaaS platform). The segment serves diverse end markets predominantly industrial, government, retail &amp; consumer. Geographically, U.S. accounts for the largest revenue contribution at 56% of total, followed by Europe at 17% and China at 8%.
Advanced Healthcare Solutions (AHS). The AHS segment supplies critical workflow solutions critical for patient care. This includes instrument sterilization solutions, instrument tracking, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions. The AHS segment has a recurring revenue base at nearly 80% with adjusted EBITDA margins in high 20s. The addressable market across AHS verticals exceeds $10 billion, with low single-digit to mid-single digit growth potential.
Capital Structure. As part of the transaction, FTV (ex RAL) will receive $1.15 billion in dividend from Ralliant Corp. Of which, $700 million will be used to repay debt. The remaining will be used for share buyback under its $550 million share repurchase authorization program. Pro forma debt post spin-off is expected to be $3.2 billion, with cash &amp; cash equivalents at $1.2 billion. Based on TTM Q1 2025 adjusted EBITDA, leverage is 2.7x, with the target to bring it down to 2.5x in the next 12-18 months.
Ralliant Corp
Ralliant Corp will include the Precision Technologies business comprising a portfolio of brands such as Gems, Tektronix, Setra, Qualitrol, among others. It offers advanced instrumentation and precision measurement solutions to aerospace, defense, electronics, automotive, and industrial manufacturing.
The Company will operate via two segments &#8211; Test and Measurement (~56% of total sales) and Sensors and Safety Systems (44% of total sales).
Capital Structure
As part of the transaction, Ralliant will issue new debt of $1.15 billion via a term loan. The proceeds will be used to fund the cash distribution to Fortive. Pro forma cash post the transaction will be $150 million, implying a net debt of $1.0 billion. Additionally, RAL will have access to a total liquidity of $900 million comprising an undrawn revolving credit facility of $750 million and $150 million in undrawn term loans. Based on TTM Q1 2025 adjusted EBITDA, leverage is 1.9x, which is within the Company's target range of 1.5x-2.0x.
Financial Outlook
FTV (ex RAL)
We expect FTV (ex RAL) to deliver revenue growth of 3.6% in FY25. We expect margins to expand, supported by higher mix of recurring revenue and operating leverage. As such, we model EBITDA margins of 29% in FY25, up 50 bps YOY. The combination of solid revenue growth and margin expansion should drive EPS higher. We model adjusted EPS of $2.56 in FY25, up 6% YOY.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="710" height="148" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9.png" alt="" class="wp-image-14987" style="width:506px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9.png 710w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9-300x63.png 300w" sizes="(max-width: 710px) 100vw, 710px" /><figcaption class="wp-element-caption">Source: GSBR Research Estimates, Company filings</figcaption></figure>
Ralliant Corp (RAL)
We expect RAL to deliver revenue growth of 3.5% in FY25 and 4.0% in FY:26. We expect adjusted EBITDA to grow faster than revenue, implying margin expansion. As such, we model EBITDA margins of 23.7% in FY25 and 23.9% in FY:26. We forecast adjusted EPS of $3.40 in FY25 and $3.60 in FY26.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="704" height="170" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10.png" alt="" class="wp-image-14988" style="width:501px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10.png 704w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10-300x72.png 300w" sizes="(max-width: 704px) 100vw, 704px" /><figcaption class="wp-element-caption">Source: GSBR Research Estimates, Company filings</figcaption></figure>
Valuation
FTV (ex RAL) 
We value FTV (ex RAL) using the EV/EBITDA multiple. We value IOS segment at 19x 2026E adjusted EBITDA of $1,049 million, and ASH segment at 12.6x 2026E adj. EBITDA of $395 million, in line with the peer group average. Corporate expense is valued at 12x. We use debt of ~$3.2 billion and cash of $1.2 billion (factoring in ~$1.15 billion of proceeds from RAL which will be used to pare debt). We assume ~339 million shares outstanding. Our 12-month price target is $62.70.
Ralliant Corp (RAL) 
We value RAL using the EV/EBITDA multiple. We apply a multiple of 12.4x 2026E adjusted EBITDA of $557 million, at a discount to the peer group average given RAL's lower growth and margin profile and higher debt. We assume ~113 million shares outstanding. Our 12-month price target is $52.40.

Conclusion: Of the two, Fortive (ex RAL) seems a better investment opportunity and could attract higher investor interest given its higher margin profile, reducing debt and share buyback program.

Long Ideas

Opinion

Fortive Corporation Common Stock When-Issued

FTVW

RALW

Fortive Or Its Spin-Off Ralliant: Which Stock Is A Better Buy?

WETH

WeTouch Secures Nasdaq Extension To File Delinquent 10-K And 10-Q Reports

RBC Capital analyst Irene Nattel reiterates Alimentation Couche-Tard (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATD#TSX">ATD</a>) with a Outperform and maintains C$94 price target.

TSX:ATD

RBC Capital Reiterates Outperform on Alimentation Couche-Tard, Maintains C$94 Price Target

Press Releases

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus Provides 2025 Corporate and Financial Update

Management

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Earnings

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

ROIV

Chardan Capital

HC Wainwright & Co.

Jefferies

JMP Securities

4월 3일 수요일, 아르부투스 바이오파마(Arbutus Biopharma) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) 주식은 회사가 법정에서 모더나 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)에 대한 소송을 제기할 허가를 받은 후 15% 이상 급등했다.
What Happened: 아르부투스는 모더나가 코로나 백신을 개발할 때 사용한 메신저 RNA 기술에 대한 특허 침해 사건을 2022년 2월에 처음 제기했다
참고 자료: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38076756/cathie-wood-says-tesla-is-biggest-ai-project-in-world-sees-convergence-of-3-key-technolo">Cathie Wood Says Tesla Is &#8216;Biggest AI Project&#8217; In World, Sees Convergence Of 3 Key Technologies Driving Stock To $2,000</a>
그러나 이후에 이 사건은 여러 기술적 문제와 용어에 대한 법적 분쟁에 엉켰다.
2023년 4월 항소 법원은 모더나의 편을 들었지만 지난 2월 특허 침해 청구를 다루는 사법 절차인 마크맨(Markman) 청문회에서 판사는 모더나를 상대로 제기된 두 가지 청구에 대해 의견이 분분했다.
그러나 수요일, 미국 델라웨어 지방 법원 판사 미첼 S. 골드버그(Mitchell S. Goldberg) 판사는 &#8220;포뮬레이션 중 mRNA의 최소 70% / 최소 80% / 약 90%가 부분적으로 완전히 구별된다&#8221;는 아르부투스의 주장을 허용했다. 지질 소포 안에 함유되어 있다."
기술적이긴 하지만 이는 아르부투스의 주장에서 중요한 승리였다.
랭글리 캐피털(Rangeley Capital)의 크리스 데무스(Chris DeMuth)는 시킹 알파(Seeking Alpha)에 <a href="https://seekingalpha.com/news/4086921-arbutus-biopharma-jumps-after-patent-victory-in-fight-with-moderna?feed_item_type=news">전했다:</a> &#8220;오늘 청구권 구성 순서는 분쟁 조건에 대한 Arbutus의 제안과 사실상 동일했다.&#8221;
&#8220;이것은 이제 모더나가 아르부투스의 조건에서 벌어질 소송에의해 직면하게 되는 큰 문제다. ABUS/ROIV가 우선적으로 노출되어 있음을 밝혀야겠다. 오늘의 판결은 우리가 이것이 유용한 지적재산권이며, ABUS가 성공적으로 이를 방어할 것이라는 주장과 일관성이 있다.&#8221;
이 사건이 언제 재판에 넘어가거나, 법원의 명령에 따라 언제 해결되는지는 알려져 있지 않다.
ABUS 주가 움직임: 수요일 아르부투스의 주가는 15.87% 상승한 2.92달러에 마감했다.
이제 읽어보세요: <a href="https://www.benzinga.com/markets/equities/24/04/38074584/crude-oil-climbs-to-5-month-high-in-q1-analysts-expect-high-prices-to-persist-in-q2">1분기에 원유 가격이 상승, 2분기에도 높은 가격 유지 전망</a>
Shutterstock의 이미지

Comments

Arbutus Biopharma

뉴스

에 대한 최신 뉴스 Arbutus Biopharma (NASDAQ:ABUS) 주식

목요일, 4월 04, 2024

뉴스

파트너 / 기고자

벤징가 글로벌